Green and precise chemistry is key to sustainable pharmaceutical manufacturing. Discuss with reference to recent advances in milder synthetic methods.

Green chemistry designs reactions that use fewer hazardous reagents and produce less waste. Precise chemistry changes exactly the atom intended. A 2026 Science study from the University of Chicago swapped a ring carbon for nitrogen under mild conditions [1], which shows that both goals can advance together.

Why green and precise chemistry matter

• Fewer harsh reagents: earlier C→N swaps needed powerful oxidants that damaged other parts of the molecule [1]. Milder routes mean less hazardous waste.
• Fewer steps: editing an existing scaffold avoids rebuilding the molecule from scratch, which saves solvents, energy and time.
• Better drugs: a single C→N swap can change a molecule's solubility and target binding [1].

Recent advances in milder methods

• Skeletal editing: chemists now insert, delete or swap single atoms in a molecule's core, not just in the groups around it.
• Triplet-nitrene C→N swap: the method uses a nitrene state that was earlier dismissed as unproductive. The ring opens, its atoms rearrange and it closes again with N in C's place [1].
• Results: it gave a 73% yield on an indole that existing methods could not convert. The team also edited a Vinca alkaloid (an anti-cancer compound), showing late-stage editing of complex molecules [1].
• Related edits, such as oxygen-to-nitrogen swaps and nitrogen-atom insertion, are widening the toolkit.

Limitations

• It has been shown on only a few examples. "Mild" is a comparison, since cost and waste have not been measured.
• A lab yield is not factory scale, and each new analogue still needs trials.
• Section 3(d), Patents Act, 1970 may bar patents on analogues that do not show enhanced efficacy.

Relevance for India

• The PRIP scheme (₹5,000 crore) funds pharma-medtech R&D [2], including Centres of Excellence at seven NIPERs [3].
• Breakthroughs like this come from basic university chemistry, so a scheme tilted towards industry projects may underfund upstream methods research.

Milder, precise methods therefore bring drug discovery in line with sustainability. The Department of Pharmaceuticals should fund synthetic-methods research at the NIPER Centres of Excellence. It should also use the 2023 National Policy on R&D and Innovation in Pharma-MedTech [4] to link academic labs with industry. This would help India's generics-led industry become a cleaner innovator and advance SDGs 3, 9 and 12.